JAZZ
Jazz Pharmaceuticals plc
121.23
USD
This page is just a preview of the data found in TrendSpider’s full version
Jazz Pharmaceuticals plc stock is down -8.2% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.94% of the previous 16 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 80% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 23 Oct 17:47 | 17 Nov, 2023 | 140.00 | 368 | ||
| 23 Oct 17:47 | 17 Nov, 2023 | 140.00 | 368 | ||
| 25 Oct 14:41 | 17 Nov, 2023 | 135.00 | 292 | ||
| 25 Oct 18:22 | 17 Nov, 2023 | 135.00 | 292 | ||
| 27 Oct 18:50 | 17 Nov, 2023 | 135.00 | 499 | ||
| 07 Nov 16:18 | 17 Nov, 2023 | 135.00 | 945 | ||
| 09 Nov 16:36 | 15 Dec, 2023 | 130.00 | 325 | ||
| 09 Nov 16:55 | 15 Dec, 2023 | 130.00 | 325 | ||
| 13 Nov 18:11 | 15 Dec, 2023 | 130.00 | 1080 | ||
| 13 Nov 18:50 | 15 Dec, 2023 | 130.00 | 1080 |
Jazz Pharmaceuticals plc identifies, develops, commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi, Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the. treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for. adults with newly-diagn
